BGF Global Equity Income SR2 USD |
Performance History | 30/09/2024 |
Growth of 1,000 (EUR) |
Fund | - | - | - | 12.4 | 12.0 | |
+/-Cat | - | - | - | 2.6 | -1.2 | |
+/-Idx | - | - | - | 5.2 | -2.1 | |
Category: Global Equity Income | ||||||
Benchmarks: Morningstar Gbl High Div Yl... |
Key Stats | ||
NAV 04/10/2024 | USD 12.24 | |
Day Change | 0.77% | |
Morningstar Category™ | Global Equity Income | |
ISIN | LU2471417662 | |
Fund Size (Mil) 30/08/2024 | USD 976.91 | |
Share Class Size (Mil) 04/10/2024 | USD 0.01 | |
Max Initial Charge | - | |
Ongoing Charge 15/04/2024 | 0.89% |
Investment Objective: BGF Global Equity Income SR2 USD |
The Fund seeks an above average income from its equity investments without sacrificing long term capital growth. The Fund invests globally at least 70% of its total assets in the equity securities of companies domiciled in, or exercising the predominant part of their economic activity in, developed markets. Currency exposure is flexibly managed. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Olivia Treharne 01/02/2020 | ||
Molly Greenen 12/01/2022 | ||
Inception Date 27/04/2022 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI ACWI NR USD | Morningstar Gbl High Div Yld NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BGF Global Equity Income SR2 USD | 31/08/2024 |
|
|
Top 5 Holdings | Sector | % |
Microsoft Corp | Technology | 4.91 |
AstraZeneca PLC | Healthcare | 3.17 |
Texas Instruments Inc | Technology | 3.17 |
Apple Inc | Technology | 3.14 |
Novo Nordisk AS Class B | Healthcare | 3.13 |
Increase Decrease New since last portfolio | ||
BGF Global Equity Income SR2 USD |